Preliminary unaudited Q4 and Full Year 2025 net Attruby®product revenue of $146.0 million and $362.4 million, respectively ...

Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...

Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.

Postmenopausal Woman With Photophobia and a Severe Headache A 51-year-old woman with a history of migraine presents with “the worst headache of her life,” accompanied by blurred vision and light ...

The successful commercialization of Attruby could establish BridgeBio as a key player in the ATTR-CM market, significantly improving its path to profitability.